CCL2 and atherosclerosis: Blocking MCP-1, a chemokine also involved in VSMC proliferation and migration (Fougerat et al., 2012), has been demonstrated to be efficient to limit atherosclerosis progression and to increase plaque stability in the established atherosclerosis ApoE−/− mouse model (Ni et al., 2001; Inoue et al., 2002).